Pharmalink AB, a Stockholm, Sweden-based specialty pharma company developing high value products for niche indications, raised SEK96m (€11m/US$15m) in Series C financing.
The new funds will be used to:
– prepare for pivotal studies with Busulipo™, a conditioning agent for use in cancer patients prior to hematopoietic stem cell transplantation (HSCT), and advance the product towards market approval,
– complete the pivotal Phase IIb study with Nefecon, a potential disease-modifying treatment for patients with primary IgA nephropathy at risk of developing end-stage renal disease,
– seek commercial partners for its products outside the Nordic region, and
– facilitate in-licensing or acquisition of additional opportunities for commercialisation in the Nordic region.
Led by Johan Häggblad, Managing Director, Pharmalink is also actively seeking opportunities to acquire or in-licence product opportunities in niche and hospital care indications.